Register Login
Register to leave comments
  • News bot March 26, 2026, 8:22 p.m.

    📋 INHIBIKASE THERAPEUTICS, INC. (IKT) - Financial Results

    Filing Date: 2026-03-26

    Accepted: 2026-03-26 16:21:52

    Event Type: Financial Results

    Event Details:

    INHIBIKASE THERAPEUTICS, INC. (IKT) Reports the reporting period Financial Results INHIBIKASE THERAPEUTICS, INC. (IKT) announced its financial results for the period ending the reporting period. Key Financial Highlights:
    • Revenue: Not disclosed
    • Net Income: Not disclosed
    • EPS: Not disclosed
    • Cash and equivalents: 139220208
      • placed to advance enrollment in our global pivotal study, called IMPROVE
        • anticipated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include our ability to commence and execute a Phase 3 study to evaluate IKT-001 as a treatment for PAH, as well as such other factors that are included in our periodic reports on Form 10-K and Form 10-Q that we file with the U.S. Securities and Exchange Commission. Any forward-looking statement in this release speaks only as of the date of this release. Inhibikase undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. Contacts: Investor Relations: Michael Moyer LifeSci Advisors mmoyer@lifesciadvisors.com —tables to follow— Inhibikase Therapeutics, Inc. Consolidated Balance Sheets December 31,2025

    📊 Key Financial Metrics (Year-over-Year Comparison):

    Metric 2025 2024 Change ($) Change (%)
    Current Assets Prepaid Expenses Other Current Assets 343.37K 826.47K $-483.10K -58.45%
    Current Liabilities Accounts Payable 1.16M 943.02K $215.03K +22.80%
    Costs And Expenses Selling General Administrative 23.56M 11.38M $12.18M +107.01%
    Loss From Operations 51.97M 28.59M $23.39M +81.80%
    Interest Income 3.72M 1.07M $2.65M +247.47%
    Net Loss 48.26M 27.52M $20.74M +75.36%
    Net Loss Per Share 0.49 1.16 $-0.67 -57.76%
    Cash Flows From Operating Activities Net Loss 48.26M 27.52M $20.74M +75.36%
    Changes In Operating Assets And Liabilities Operating Lease Right Of Use Assets 101.44K 120.79K $-19.35K -16.02%
    Changes In Operating Assets And Liabilities Prepaid Expenses Other Current Assets 532.73K 616.52K $-83.79K -13.59%
    Changes In Operating Assets And Liabilities Accounts Payable 146.83K 271.78K $-124.95K -45.98%
    Changes In Operating Assets And Liabilities Operating Lease Liabilities 110.52K 129.70K $-19.18K -14.79%
    Prepaid Expenses and Other Current Assets 343.37K 826.47K $-483.10K -58.45%
    Accounts Payable 1.16M 943.02K $215.03K +22.80%
    Selling, General & Administrative 23.56M 11.38M $12.18M +107.01%
    Loss from Operations 51.97M 28.59M $23.39M +81.80%
    Interest Income 3.72M 1.07M $2.65M +247.47%
    Net Loss 48.26M 27.52M $20.74M +75.36%
    Operating Lease Liabilities 110.52K 129.70K $-19.18K -14.79%

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: INHIBIKASE THERAPEUTICS, INC.
    • Ticker Symbol: IKT

Search

News categories